300,000 Shares in Septerna, Inc. (NASDAQ:SEPN) Purchased by Woodline Partners LP

Woodline Partners LP bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 300,000 shares of the company's stock, valued at approximately $6,870,000. Woodline Partners LP owned 0.68% of Septerna as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. RA Capital Management L.P. bought a new stake in Septerna in the 4th quarter valued at about $160,205,000. TRV GP V LLC acquired a new position in Septerna during the 4th quarter worth approximately $142,337,000. TRV GP VI LLC acquired a new position in shares of Septerna during the fourth quarter worth $72,191,000. Samsara BioCapital LLC acquired a new position in shares of Septerna during the fourth quarter worth $63,399,000. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Septerna during the fourth quarter worth $59,301,000.

Analyst Upgrades and Downgrades

SEPN has been the subject of several recent analyst reports. Wells Fargo & Company increased their price objective on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research report on Friday, May 16th. Cantor Fitzgerald raised their target price on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th.

Septerna Stock Performance

SEPN stock traded up $0.19 during midday trading on Thursday, hitting $9.91. The company's stock had a trading volume of 179,512 shares, compared to its average volume of 709,822. The firm's 50-day moving average is $6.93 and its 200-day moving average is $13.48. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The firm had revenue of $0.22 million for the quarter. As a group, research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Insider Activity at Septerna

In other Septerna news, Director Alan Ezekowitz purchased 41,355 shares of the stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of $6.00 per share, with a total value of $248,130.00. Following the completion of the acquisition, the director now owns 104,101 shares in the company, valued at $624,606. This trade represents a 65.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Septerna Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.